SS6-6 Toll-like receptor 2 and deregulated cytokine signaling contribute to gastric inflammation and tumourigenesis

Catherine L. Kennedy; Hazel Tye; Meri Najdovska; Louise McLeod; Luke O'neill; Paul J. Hertzog; Ashley Mansell; Brendan J. Jenkins

doi:10.1016/j.cyto.2010.07.196

SS6-6 Toll-like receptor 2 and deregulated cytokine signaling contribute to gastric inflammation and tumourigenesis

Cytokine 52(1-2): 47-47

Article 2010 English

Related publications

Letter2006

DisSARMing Toll-like receptor signaling

Luke O'neill

Nature Immunology

Article2006

Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation

Ashley Mansell, Rosealee Smith, Sarah Doyle, Pearl Gray, Jennifer E Fenner, Peter J. Crack, Sandra E. Nicholson, Douglas J. Hilton, Luke O'neill, Paul J. Hertzog

Nature Immunology

Article2001

Toll-like receptor 2 signaling is important for fas ligand on NKT cells, may contribute to liver injury induced by Salmonella infection

Hideyuki Shimizu, Yoshide Fukuda, Isao Nakano, Yoshiaki Katano, K. Nagano, S. Yokozaki, Mamiko Takeuchi, Tetsuo Hayakawa, Osamu Takeuchi, Akira Shizuo, Tetsuya Matsuguchi, Yasunobu Yoshikai

Gastroenterology

Article2010

Toll-like receptor signalling during infection and inflammation

Luke O'neill

The biomedical & life sciences collection.

Article2008

Primer: Toll-like receptor signaling pathways—what do rheumatologists need to know?

Luke O'neill

Nature Clinical Practice Rheumatology

SS6-6 Toll-like receptor 2 and deregulated cytokine signaling contribute to gastric inflammation and tumourigenesis

Abstract

Discussion(0)

Related publications

DisSARMing Toll-like receptor signaling

Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation

Toll-like receptor 2 signaling is important for fas ligand on NKT cells, may contribute to liver injury induced by Salmonella infection

Toll-like receptor signalling during infection and inflammation

Primer: Toll-like receptor signaling pathways—what do rheumatologists need to know?